|
|
||||||||||||||
|
|
|||||||||||||||
ORIGINAL ARTICLE |
1 Department of Histopathology, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
2 Institute of Cancer Research, Cancer Screening Evaluation Unit, Sutton, Surrey SM2 5NG, UK
3 Department of Histopathology, St Bartholomews Medical School, London EC1A 9DS, UK
4 Department Histopathology, Broomfield Hospital, Chelmsford, Essex CM1 7ET, UK
5 Department of Pathology, Royal Group of Hospitals Trust, Belfast BT12 6BA, Northern Ireland, UK
6 Department of Histopathology, Addenbrookes Hospital, Cambridge CB2 2QQ, UK
7 Department of Histopathology, The John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK
8 Pathology Department, University College Hospital, Galway, Ireland
9 Department of Histopathology, Llandough Hospital, Penarth, S Glamorgan CF64 2XX, Wales, UK
10 Department of Pathology, Countess of Chester Hospital, Chester, Cheshire CH2 1UL, UK
11 Department of Histopathology, St James University Hospital, Leeds LS9 7TF, UK
12 Medical Solutions, Harley Street, London W1G 9QP, UK
13 Department of Histopathology, Wythenshaw Hospital, Wythenshaw, Manchester M23 9LT, UK
14 Department of Histopathology, University Hospital of North Tees, Hardwick, Stockton on Tees TS19 8PE, UK
15 Department of Histopathology, University Hospitals Coventry and Warwickshire, Coventry, West Midlands CV1 4FH, UK
16 Department of Cellular Pathology, St Georges Hospital, Tooting, London SW17 0QT, UK
17 Department of Pathology, Royal Bournemouth Hospital, Bournemouth, Dorset BH7 7DW, UK
18 NHS Cancer Screening Programmes, Sheffield ST10 3TH, UK
19 Department of Histopathology, St Vincents University Hospital, Dublin 4, Ireland
20 Department of Pathology, University of Dundee, Dundee, Tayside DD1 9SY, UK
21 Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester Royal Infirmary, Leicester LE1 5WW, UK
22 NHS Breast and Cervical Screening Programmes, Sheffield ST10 3TH, UK
Correspondence to:
Professor I O Ellis
Department of Histopathology, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; ian.ellis{at}nottingham.ac.uk
Background: This article presents the results and observed effects of the UK National Health Service Breast Screening Programme (NHSBSP) external quality assurance scheme in breast histopathology.
Aims/Methods: The major objectives were to monitor and improve the consistency of diagnoses made by pathologists and the quality of prognostic information in pathology reports. The scheme is based on a twice yearly circulation of 12 cases to over 600 registered participants. The level of agreement was generally measured using
statistics.
Results: Four main situations were encountered with respect to diagnostic consistency, namely: (1) where consistency is naturally very highthis included diagnosing in situ and invasive carcinomas (and certain distinctive subtypes) and uncomplicated benign lesions; (2) where the level of consistency was low but could be improved by making guidelines more detailed and explicitthis included histological grading; (3) where consistency could be improved but only by changing the system of classificationthis included classification of ductal carcinoma in situ; and (4) where no improvement in consistency could be achievedthis included diagnosing atypical hyperplasia and reporting vascular invasion. Size measurements were more consistent for invasive than in situ carcinomas. Even in cases where there is a high level of agreement on tumour size, a few widely outlying measurements were encountered, for which no explanation is readily forthcoming.
Conclusions: These results broadly confirm the robustness of the systems of breast disease diagnosis and classification adopted by the NHSBSP, and also identify areas where improvement or new approaches are required.
Abbreviations: DCIS, ductal carcinoma in situ; EQA, external quality assessment; EWGBSP, European Commission working group on breast screening pathology; NHSBSP, National Health Service Breast Screening Programme
Keywords: breast; external quality assurance; histopathology; pathology; quality assurance
This article has been cited by other articles:
![]() |
E. A. Rakha, M. E. El-Sayed, A. H.S. Lee, C. W. Elston, M. J. Grainge, Z. Hodi, R. W. Blamey, and I. O. Ellis Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma J. Clin. Oncol., July 1, 2008; 26(19): 3153 - 3158. [Abstract] [Full Text] [PDF] |
||||
![]() |
J A M Gray, J Patnick, and R G Blanks Maximising benefit and minimising harm of screening BMJ, March 1, 2008; 336(7642): 480 - 483. [Full Text] [PDF] |
||||
![]() |
EQA deems UK breast screening satisfactory Qual. Saf. Health Care, April 1, 2007; 16(2): 115 - 115. [Full Text] [PDF] |
||||
![]() |
D M Parham, D Coleman, S Kodikara, S Moss, I O Ellis, S Al-sam, N Anderson, L Bobrow, I Buley, C E Connolly, et al. The NHS breast screening programme (pathology) EQA: experience in recent years relating to issues involved in individual performance appraisal J. Clin. Pathol., February 1, 2006; 59(2): 130 - 137. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |